Molecular Templates Inc Stock News

AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel thera

AUSTIN, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discover

Molecular Templates Inc. (MTEM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the sever

AUSTIN, Texas, May 26, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery

Penny stocks to watch under $1 The post 9 Hot Penny Stocks Under $0.99 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -56% and 63.99%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the sto

Molecular Templates (NASDAQ: MTEM ) stock is rocketing higher on Friday after the company got approval from the FDA. That FDA approval has to do with its IND application for its cancer treatment.

AUSTIN, Texas, March 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discove

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discover

AUSTIN, Texas, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discover

Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of 8.33% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock

AUSTIN, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discover

AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular Templates” or “MTEM”) a clinical-stage biopharmaceutical company focused on the discovery

AUSTIN, Texas, May 17, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery

Molecular Templates Inc. (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.